{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:18:33Z","timestamp":1787739513235,"version":"build-2784847793"},"reference-count":51,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.3724\/abbs.2026112","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:35:38Z","timestamp":1781235338000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["EZH2-dependent STAT3 stabilization drives pomalidomide resistance and is targetable by EZH2 inhibition in multiple myeloma"],"prefix":"10.3724","author":[{"given":"Xinyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"Rajkumar SV","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol, 2020, 95: 548-567.","journal-title":"Am J Hematol"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"Kumar SK","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F. Multiple myeloma. Nat Rev Dis Primers, 2017, 3:","journal-title":"Nat Rev Dis Primers"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"Miguel JS","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol, 2013, 14: 1055-1066.","journal-title":"Lancet Oncol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"Holstein SA","year":"2017","unstructured":"Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs, 2017, 77: 505-520.","journal-title":"Drugs"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"e1077","DOI":"10.1016\/j.clml.2025.08.003","volume":"25","author":"Ntanasis-Stathopoulos I","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Malandrakis P, Filippatos C, Maganas S, Fotiou D, Theodorakakou F, Spiliopoulou V. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed\/refractory multiple myeloma: a single-center experience. Clin Lymphoma Myeloma Leuk, 2025, 25: e1077-e1085.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/blood-2023-174177","volume":"142","author":"Patel R","year":"2023","unstructured":"Patel R, Patel D, Patel Z, Patel M, Chitkara A, Yang C, Onyechi A. Disparities in palliative care utilization in deceased lymphoma patients: a nationwide analysis. Blood, 2023, 142:","journal-title":"Blood"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"Kr\u00f6nke J","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science, 2014, 343: 301-305.","journal-title":"Science"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2147\/OTT.S398118","volume":"18","author":"van de Donk NWCJ","year":"2025","unstructured":"van de Donk NWCJ, Bahlis NJ, Pawlyn C, Gay F, Mateos MV, Weisel K, Lonial S. The role of CELMoD agents in multiple myeloma. Onco Targets Ther, 2025, 18: 921-933.","journal-title":"Onco Targets Ther"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1007\/s12325-025-03308-2","volume":"42","author":"Touzeau C","year":"2025","unstructured":"Touzeau C, Lipe B, Khan AM, Dhakal B, Nair S, He J, Mendes J. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-4 versus real-world physician\u2019s choice of therapy from the flatiron registry in lenalidomide-refractory multiple myeloma. Adv Ther, 2025, 42: 5023-5041.","journal-title":"Adv Ther"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"Margueron R","year":"2011","unstructured":"Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature, 2011, 469: 343-349.","journal-title":"Nature"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"Kim KH","year":"2016","unstructured":"Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med, 2016, 22: 128-134.","journal-title":"Nat Med"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3390\/cancers17193111","volume":"17","author":"Verma S","year":"2025","unstructured":"Verma S, Goyal N, Goyal S, Kaur P, Gupta S. EZH2 dysregulation and its oncogenic role in human cancers. Cancers, 2025, 17:","journal-title":"Cancers"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1038\/bcj.2017.27","volume":"7","author":"Pawlyn C","year":"2017","unstructured":"Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood Cancer J, 2017, 7:","journal-title":"Blood Cancer J"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"Knutson SK","year":"2014","unstructured":"Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T.  Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma . Mol Cancer Ther, 2014, 13: 842-854.","journal-title":"Mol Cancer Ther"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood.2022017010","volume":"141","author":"Ansari-Pour N","year":"2023","unstructured":"Ansari-Pour N, Samur M, Flynt E, Gooding S, Towfic F, Stong N, Estevez MO. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma. Blood, 2023, 141: 620-633.","journal-title":"Blood"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clml.2025.08.017","volume":"26","author":"Zayad A","year":"2026","unstructured":"Zayad A, Magee G, Mansour R, Chang M, Ahmed N, Mushtaq MU, Paul B. Efficacy and safety of daratumumab, pomalidomide and dexamethasone compared to daratumumab, carfilzomib and dexamethasone in relapsed multiple myeloma: multicenter real-world experience. Clin Lymphoma Myeloma Leukemia, 2026, 26: 94-105.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1186\/s12885-025-15083-y","volume":"25","author":"Boccadoro M","year":"2025","unstructured":"Boccadoro M, Belotti A, Bombaci F, Bringhen S, Buda G, Cafro AM, Caimmi M. Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework. BMC Cancer, 2025, 25:","journal-title":"BMC Cancer"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12185-025-04087-w","volume":"123","author":"Yi JH","year":"2026","unstructured":"Yi JH, Park SS, Min CK, Lee JH, Eom HS, Lee JH, Kim K. Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone. Int J Hematol, 2026, 123: 263-269.","journal-title":"Int J Hematol"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","volume":"139","author":"Zamagni E","year":"2022","unstructured":"Zamagni E, Barbato S, Cavo M. How I treat high-risk multiple myeloma. Blood, 2022, 139: 2889-2903.","journal-title":"Blood"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"98348","DOI":"10.18632\/oncotarget.21311","volume":"8","author":"Yu T","year":"2017","unstructured":"Yu T, Wang Y, Hu Q, Wu WN, Wu Y, Wei W, Han D. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. Oncotarget, 2017, 8: 98348-98359.","journal-title":"Oncotarget"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"1076458","DOI":"10.3389\/fcell.2023.1076458","volume":"11","author":"Sbirkov Y","year":"2023","unstructured":"Sbirkov Y, Schenk T, Kwok C, Stengel S, Brown R, Brown G, Chesler L. Dual inhibition of EZH2 and G9A\/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells. Front Cell Dev Biol, 2023, 11:","journal-title":"Front Cell Dev Biol"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","volume":"13","author":"Straining, PharmD R","year":"2022","unstructured":"Straining, PharmD R, Eighmy, PharmD W. Tazemetostat: EZH2 inhibitor. JADPRO, 2022, 13: 158-163.","journal-title":"JADPRO"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"115461","DOI":"10.1016\/j.ejmech.2023.115461","volume":"256","author":"Yang X","year":"2023","unstructured":"Yang X, Xu L, Yang L. Recent advances in EZH2-based dual inhibitors in the treatment of cancers. Eur J Med Chem, 2023, 256:","journal-title":"Eur J Med Chem"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","volume":"16","author":"Ma A","year":"2020","unstructured":"Ma A, Stratikopoulos E, Park KS, Wei J, Martin TC, Yang X, Schwarz M. Discovery of a first-in-class EZH2 selective degrader. Nat Chem Biol, 2020, 16: 214-222.","journal-title":"Nat Chem Biol"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"118106","DOI":"10.1016\/j.ejmech.2025.118106","volume":"299","author":"Tang M","year":"2025","unstructured":"Tang M, Gong M, Liu X, Zhang T, Liu Z, Song D. Recent update on the development of EZH2 inhibitors and degraders for cancer therapy. Eur J Med Chem, 2025, 299:","journal-title":"Eur J Med Chem"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13148-018-0554-4","volume":"10","author":"Herviou L","year":"2018","unstructured":"Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, M\u00fcller-Tidow C, Vincent L. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenet, 2018, 10:","journal-title":"Clin Epigenet"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1878-0261.12157","volume":"12","author":"Dimopoulos K","year":"2018","unstructured":"Dimopoulos K, S\u00f8gaard Helbo A, Fibiger Munch-Petersen H, Sj\u00f6 L, Christensen J, Sommer Kristensen L, Asmar F. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol Oncol, 2018, 12: 180-195.","journal-title":"Mol Oncol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"Morschhauser F","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol, 2020, 21: 1433-1442.","journal-title":"Lancet Oncol"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-018-0148-5","volume":"6","author":"Tremblay-LeMay R","year":"2018","unstructured":"Tremblay-LeMay R, Rastgoo N, Pourabdollah M, Chang H. EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomark Res, 2018, 6:","journal-title":"Biomark Res"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2014.60","volume":"28","author":"Dimopoulos MA","year":"2014","unstructured":"Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia, 2014, 28: 1573-1585.","journal-title":"Leukemia"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/1535-7163.MCT-15-0486","volume":"15","author":"Hernando H","year":"2016","unstructured":"Hernando H, Gelato KA, Lesche R, Beckmann G, Koehr S, Otto S, Steigemann P. EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes. Mol Cancer Ther, 2016, 15: 287-298.","journal-title":"Mol Cancer Ther"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41467-025-56506-5","volume":"16","author":"Liu R","year":"2025","unstructured":"Liu R, Li Z, Chen R, Fang Z, Liu Z, Liu H. EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction. Nat Commun, 2025, 16:","journal-title":"Nat Commun"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2023-179331","volume":"142","author":"Ting PY","year":"2023","unstructured":"Ting PY, Borikar S, Kerrigan JR, Thomsen NM, Aghania E, Hinman AE, Pizzato N. Targeted degradation of the Wiz transcription factor for gamma globin de-repression. Blood, 2023, 142:","journal-title":"Blood"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","volume":"25","author":"Kim J","year":"2018","unstructured":"Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep, 2018, 25: 2808-2820.e4.","journal-title":"Cell Rep"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.3390\/ijms21249501","volume":"21","author":"Wang J","year":"2020","unstructured":"Wang J, Wang GG. No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function. Int J Mol Sci, 2020, 21:","journal-title":"Int J Mol Sci"},{"key":"CITATION36","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.10075","author":"Xu L","year":"2019","unstructured":"Xu L, Tang H, Wang K, Zheng Y, Feng J, Dong H, Jin Y. Pharmacological inhibition of EZH2 combined with DNA-damaging agents interferes with the DNA damage response in MM cells. Mol Med Report, 2019,","journal-title":"Mol Med Report"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"e1291106","DOI":"10.1080\/2162402X.2017.1291106","volume":"6","author":"Lu C","year":"2017","unstructured":"Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. OncoImmunology, 2017, 6:","journal-title":"OncoImmunology"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"Yu H","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 2009, 9: 798-809.","journal-title":"Nat Rev Cancer"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nri1995","volume":"7","author":"Yu H","year":"2007","unstructured":"Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 2007, 7: 41-51.","journal-title":"Nat Rev Immunol"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"e923","DOI":"10.1097\/SLA.0000000000004705","volume":"276","author":"Gleisner AL","year":"2022","unstructured":"Gleisner AL, Moss A, Friedman C, Suresh K, Grunwald G, Torphy RJ, Leonard LD. De-implementation of axillary dissection in women with breast cancer is largely driven by site-level contextual effects. Ann Surg, 2022, 276: e923-e931.","journal-title":"Ann Surg"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1073\/pnas.1503152112","volume":"112","author":"Dasgupta M","year":"2015","unstructured":"Dasgupta M, Dermawan JKT, Willard B, Stark GR. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci USA, 2015, 112: 3985-3990.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"5765","DOI":"10.1172\/JCI134217","volume":"130","author":"M\u00fcller A","year":"2020","unstructured":"M\u00fcller A, Dickmanns A, Resch C, Sch\u00e4kel K, Hailfinger S, Dobbelstein M, Schulze-Osthoff K. The CDK4\/6-EZH2 pathway is a potential therapeutic target for psoriasis. J Clin Invest, 2020, 130: 5765-5781.","journal-title":"J Clin Invest"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41419-020-03096-3","volume":"11","author":"Wu Z","year":"2020","unstructured":"Wu Z, Liu H, Sun W, Du Y, He W, Guo S, Chen L. RNF180 mediates STAT3 activity by regulating the expression of RhoC via the proteasomal pathway in gastric cancer cells. Cell Death Dis, 2020, 11:","journal-title":"Cell Death Dis"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"e70199","DOI":"10.1002\/ddr.70199","volume":"86","author":"Qu X","year":"2025","unstructured":"Qu X, Ma W, Ma X, Liu J, Yang X, He D, Sun Y. Study on the mechanism of aspirin alleviating Kawasaki disease with coronary artery lesions by inducing TRAF6 to regulate STAT3 ubiquitination and inhibit Th17 cell differentiation. Drug Dev Res, 2025, 86:","journal-title":"Drug Dev Res"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fgene.2019.00422","volume":"10","author":"Lei A","year":"2019","unstructured":"Lei A, Chen L, Zhang M, Yang X, Xu L, Cao N, Zhang Z. EZH2 regulates protein stability via recruiting USP7 to mediate neuronal gene expression in cancer cells. Front Genet, 2019, 10:","journal-title":"Front Genet"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"e02087-16","DOI":"10.1128\/JVI.02087-16","volume":"91","author":"Yang L","year":"2017","unstructured":"Yang L, Wang R, Ma Z, Xiao Y, Nan Y, Wang Y, Lin S. Porcine reproductive and respiratory syndrome virus antagonizes JAK\/STAT3 signaling via nsp5, which induces STAT3 degradation. J Virol, 2017, 91:","journal-title":"J Virol"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"9599","DOI":"10.1158\/0008-5472.CAN-10-1293","volume":"70","author":"Kujawski M","year":"2010","unstructured":"Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J.  Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects . Cancer Res, 2010, 70: 9599-9610.","journal-title":"Cancer Res"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"42177","DOI":"10.1038\/s41598-025-26175-x","volume":"15","author":"Wang X","year":"2025","unstructured":"Wang X, He M, Zhou L, Chen W. EZH2 expression in hepatocellular carcinoma and its relationship with circadian rhythm-related genes. Sci Rep, 2025, 15:","journal-title":"Sci Rep"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","volume":"23","author":"Kim E","year":"2013","unstructured":"Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell, 2013, 23: 839-852.","journal-title":"Cancer Cell"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"Gan L","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res, 2018, 6:","journal-title":"Biomark Res"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.7150\/jca.50675","volume":"12","author":"Zhao Y","year":"2021","unstructured":"Zhao Y, Hu Z, Li J, Hu T. EZH2 exacerbates breast cancer by methylating and activating STAT3 directly. J Cancer, 2021, 12: 5220-5230.","journal-title":"J Cancer"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/4E5461DA4DA14999A658CD2C9004FAF4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026112","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/4E5461DA4DA14999A658CD2C9004FAF4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:31:02Z","timestamp":1787736662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":51,"URL":"https:\/\/doi.org\/10.3724\/abbs.2026112","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}